Acadia Pharmaceuticals (ACAD) PT Lowered to $27 at Mizuho Securities on ACP-044 Failure, Expects "Modest Weakness" in Shares
Tweet Send to a Friend
Mizuho Securities analyst Vamil Divan lowered the price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $27.00 (from $28.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
